Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3

March 26, 2025

IDHNow for AML Sponsored Testing Program

AML is one of the most common forms of leukemia in adults, representing ~80% of all cases,¹ and up to 16% of patients may harbor an IDH1 mutation.² In fact, 85% of all AML cases have at least one somatic mutation.³

NeoGenomics has partnered with Servier to provide eligible AML patients a rapid IDH1/2 test by PCR with a 3-5 day turnaround to help you make informed treatment decisions. The program provides no-cost testing to eligible patients.

For more information and eligibility information, visit our website.

References:
1. Beaton M, Peterson GJ, O'Brien K. Acute Myeloid Leukemia: Advanced Practice Management. J Adv Pract Oncol. 2020;11(8):836-844. doi:10.6004/jadpro.2020.11.8.4.
2. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Adv. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282.
3. Yu J, Li Y, Li T, et al. Gene mutational analysis in myelodysplastic syndrome and AML. Exp Hematol Oncol. 2020;9:2. doi:10.1186/s40164-019-0158-5.

 

 

Flow Cytometry

AML MRD Flow Panel is now available to New York State clients!

AML MRD Flow Panel is a 20-biomarker panel containing unique markers that can detect aberrant overexpression in leukemic myeloblasts to complement classic markers recommended by ELN MRD Working Party. It can be used as a prognostic/predictive assay for risk assessment and treatment decision making and to monitor for relapse.

• Markers: CD7, CD11b, CD13, CD14, CD15, CD16, CD19, CD2, CD33, CD34, CD38, CD4, CD45, CD56, CD64, CD65, CD87, CD117, CD371, HLA-DR
• Limit of Detection: 0.01%

Test Details:

• Specimen Requirements:
  • Bone marrow aspirate: 2-3 mL, first pull. EDTA preferred. Sodium heparin tube acceptable.
• Turnaround Time (TAT): 1 Day (from sample receipt at testing location)
• CPT Codes*: 88184x1, 88185x19. Add 88189x1 for global.
• Level of Service: Global only

For more info, please contact your local Territory Business Manager or visit the test menu page here.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

 

To serve our customers and their patients, we evaluate our test menu regularly to align with clinical guidelines. Effective May 12th, we will improve our test offerings to serve your diagnostic needs. While specific tests will be discontinued, we have thoroughly evaluated and identified more appropriate tests from our menu that align with recommended guidelines. Below is a comprehensive list of affected tests and their recommended replacements.

Orders for the NeoTYPE^® Discovery Profile and replaced tests will not be automatically converted. Please order the new test using the appropriate requisition form or the online ordering portal to avoid testing delays.

For a complete list of test updates, click here.